An audit of the investigation and treatment of localised prostatic cancer in the South West Region

Annals of the Royal College of Surgeons of England

Volumn 81, Issue 2, 1999, Pages 133-138

  Lodge, R N ^a,b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

Prostate cancer; PSA; Regional audit; Regional management

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONSERVATIVE TREATMENT; GENERAL PRACTITIONER; HISTOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; ORCHIECTOMY; PATIENT REFERRAL; PROSTATE CANCER; PROSTATECTOMY; TIME; UNITED KINGDOM;

AGED; ENGLAND; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; TIME FACTORS;

EID: 0033034671     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hall RH. Radical prostatectomy and prostate cancer screening: the need for national audit and research. Ann R Coll Surg Engl 1994; 76: 367-72.
2. Dearnaley DP. Cancer of the prostate. BMJ 1994; 308: 780-84.
3. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localised prostate cancer. Cancer 1993; 72: 310-22.
4. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localised prostate cancer. JAMA 1992; 269: 2650-58.
5. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 1993; 153: 2529-37.
6. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. JAMA 1994; 272: 773-80.
7. Schroeder FH. Prostate cancer: to screen or not to screen? BMJ 1993; 2: 117-23.
8. Gibbons RP. Localised prostate carcinoma. Cancer 1993; 72: 2865-72.
9. Garraway WM, Alexander FE. Prostate disease: epidemiology, natural history and demographic shifts. Br J Urol 1997; 79 (Suppl 2): 3-8.
10. Johansson JE, Adami HO, Bergstrom R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early, untreated prostate cancer. JAMA 1992; 267: 2191-6.
11. Badalament RA, Miller MC, Peller PA et al. An algorithm for predicting nonorgan confined prostate cancer using the results from sextant core biopsies with PSA level. J Urol 1996; 156: 1375-80.
12. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-68.
13. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus delayed treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-46.
14. Soloway MS. Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer? Br J Urol 1998; 81: 87-95.
15. Kramer BS, Brown ML, Prorock PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993; 119: 914-23.
16. Heman-Ackah CA, Festenstein JB, Hibbert P, Harvey DJ, Bunce CJ, Gelister JSK. Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer. Br J Urol 1997; 79: 439-44.
17. Stamey TA. Diagnosis of prostate cancer: a personal view. J Urol 1992; 147: 830-32.
18. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997; 158: 687-98.
19. The British Association of Urological Surgeons. Guidelines for the Investigation and Treatment of Urological Cancers in the United Kingdom. April 1996.
20. George NJR. Natural history of localised prostate cancer managed by conservative therapy alone. Lancet 1998; 1: 490-96.
21. Whitmore WF, Warner JA, Thompson IM. Expectant management of localised prostate cancer. Cancer 1991; 67: 1091-6.